Surrey Heartlands

Joint Formulary & PAD

Leflunomide - Respiratory disease indications

You are here : Home > Formulary Search > Leflunomide - Respiratory disease indications

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Off Label
SPC
Restrictions / Comments :

Documentation

Shared Care
Leflunomide use in adult services - National shared care - update March 2025

PAD Profile

ChemicalSubstance :
Leflunomide
Indication :
Respiratory disease indications
Group Name :
Keywords :
RMOC, national shared Care, Interstitial Lung Disease (off label)
Brand Names Include :
Arava
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Leflunomide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Respiratory disease indications.

Committee Recommendations (3)

02 Jul 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Follow link to Shared Care Principles and Communication letters Shared Care principles and Communication letters

02 Aug 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

03 May 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations.

The local adaptation is:

Specialist Responsibilities

  • The initiating specialist will be expected to initiate and optimise treatment and prescribe the maintenance treatment for at least 12 weeks and until optimised.